TY - JOUR A1 - Hempel, Louisa A1 - Molnar, Jakob A1 - Gaumann, Andreas A1 - Robert, Sebastian A1 - Scheiber, Josef A1 - Kleespies, Axel A1 - Riedmann, Kristina A1 - Schreiber, Susanne A1 - Gandorfer, Beate A1 - Piehler, Armin A1 - Hempel, Dirk T1 - Detection of acquired resistance mutation ALK G1202R after treatment with alectinib and response of lorlatinib BT - A case report JF - memo - Magazine of European Medical Oncology N2 - In the era of personalized medicine, the identification of driver mutations has paved the way towards targeted therapy. With the identification of anaplastic lymphoma kinase (ALK) as an oncogenic driver mutation, ALK rearrangements became druggable by tyrosine kinase inhibitors and, thus, have improved the prognosis for patients. Nevertheless, these approaches are limited by resistances occurring within the first or second year of administering ALK inhibitors. Among the different ALK resistant mutations, G1202R is the most common mutation, located in the kinase domain of the ALK protein resulting in resistance to treatment with the first- and second-generation kinase inhibitors (e.g., crizotinib, ceritinib, brigatenib and alectinib). Conflicting reports exist regarding the efficacy of lorlatinib, a next generation ALK inhibitor. The aim of this study is to access the potential impact of lorlatinib as a second-line treatment for a metastatic progressive NSCLC disease harboring genomic alteration of ALK G1202R, an AKLi-resistant mutation. The case of a patient with advanced lung cancer and the mentioned mutation is described. KW - NSCLC KW - Next-generation ALK inhibitor KW - Resistance mechanisms KW - Next-generation sequencing KW - Molecular diagnostics Y1 - 2021 UR - https://doi.org/10.1007/s12254-021-00724-2 ER - TY - JOUR A1 - Hempel, Louisa A1 - Molnar, Jakob A1 - Robert, Sebastian A1 - Veloso, Julia A1 - Trepotec, Zeljka A1 - Englisch, Sofie A1 - Weinzierl, Philip A1 - Schick, Cordula A1 - Milani, Valeria A1 - Schweneker, Katrin A1 - Fleischmann, Bastian A1 - Scheiber, Josef A1 - Gandorfer, Beate A1 - Kleespies, Axel A1 - Hempel, Dirk A1 - Riedmann, Kristina A1 - Piehler, Armin T1 - Rare SARS-CoV-2 antibody development in cancer patients JF - Seminars in Oncology N2 - SARS-CoV-2 antibody development and immunity will be crucial for the further course of the pandemic. Until now, it has been assumed that patients who are infected with SARS-CoV-2 will develop antibodies as has been the case with other coronaviruses, like MERS-CoV and SARS-CoV. In the present study, we analyzed the development of antibodies in 77 patients with an oncologic diagnosis 26 days after positive RT-qPCR testing for SARS-CoV2. RT-qPCR and anti-SARS-CoV2-antibody methods from BGI (MGIEasy Magnetic Beads Virus DNA/RNA Extraction Kit) and Roche (Elecsys Anti-SARS-CoV-2 immunoassay) were used, respectively, according to the manufacturers’ specifications. Surprisingly, antibody development was detected in only 6 of 77 individuals with a confirmed history of COVID-19. Despite multiple testing, the remaining patients did not show measurable antibody concentrations in subsequent tests. These results undermine the previous hypothesis that SARS-CoV2 infections are regularly associated with antibody development and cast doubt on the provided immunity to COVID-19. Understanding the adaptive and humoral response to SARS-CoV2 will play a key role in vaccine development and gaining further knowledge on the pathogenesis. KW - SARS-CoV2 antibody development KW - COVID-19 KW - Cancer KW - Immunity Y1 - 2021 UR - https://doi.org/10.1053/j.seminoncol.2020.12.003 VL - 48 IS - 2 SP - 160 EP - 165 ER -